<DOC>
	<DOCNO>NCT02142166</DOCNO>
	<brief_summary>The aim study improve usability biomarkers timely prediction new complication follow cerebral hemorrhage , especially combination invasive , functional local measurement patient aneurysmal subarachnoid hemorrhage ( SAH ) . Based analyzed biomarker profile choose therapy effort assess immediate longer-term effectiveness .</brief_summary>
	<brief_title>The Role Biomarker Serum , Cerebrospinal Fluid Parenchyma Context Aneurysmal Subarachnoid Hemorrhage .</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Dialysis Solutions</mesh_term>
	<criteria>male female , age â‰¥ 18 year sign consent participation study sign consent analysis sample collect clinical routine inpatient female male patient &lt; 18 year pregnancy , lactation lack sign informed consent participation study lack sign consent analysis sample collect clinical routine take study drug within last thirty day Simultaneous participation another clinical trial ( except participation control group ) person dependent relationship employment sponsor investigator person house judicial administrative order institution</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>aneurysmal subarachnoid hemorrhage ( ASH )</keyword>
	<keyword>biomarker</keyword>
</DOC>